Rivamer

📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.

Why order from MedsBase

Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging — no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor — never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.

What Is Rivamer?

Rivamer is an oral capsule from Sun Pharma containing rivastigmine tartrate 1.5 mg. Rivastigmine is a pseudo-irreversible dual cholinesterase inhibitor — it inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The dual mechanism distinguishes it from donepezil and galantamine, which only inhibit AChE.

Rivamer from Sun Pharma is a 1.5 mg rivastigmine capsule — the starting dose for the 6–8 week titration in mild-to-moderate Alzheimer's and Parkinson's disease dementia. Titrate to the maintenance 12 mg/day dose. Always take with food to minimise the GI side effects that are characteristic of oral rivastigmine. Rivastigmine is the only cholinesterase inhibitor with a licensed indication for Parkinson's disease dementia in addition to mild-to-moderate Alzheimer's. The dual ACh + BuChE inhibition may matter more in PDD because BuChE activity is relatively preserved in PD compared with Alzheimer's.

How Does Rivamer Work?

Both Alzheimer's disease and Parkinson's disease dementia involve cholinergic neuron loss. Rivastigmine raises synaptic acetylcholine through dual enzymatic inhibition:

• Acetylcholinesterase (AChE) inhibition — the standard cholinergic mechanism shared with donepezil and galantamine. AChE is the primary ACh-degrading enzyme in healthy brain.
• Butyrylcholinesterase (BuChE) inhibition — BuChE becomes a more important ACh-degrading enzyme as Alzheimer's progresses (compensating for AChE loss) and is the dominant ACh-degrading enzyme in Parkinson's disease dementia. Inhibiting both enzymes may produce more sustained cholinergic signal in advanced disease.
• Pseudo-irreversible binding — rivastigmine binds AChE/BuChE for hours rather than minutes, allowing twice-daily dosing despite a short plasma half-life.

Onset of cognitive benefit: visible at 6–12 weeks on the maintenance 9–12 mg/day dose; peak at 6 months.

Uses and Indications

• Mild-to-moderate Alzheimer's dementia — first-line cholinesterase inhibitor
• Parkinson's disease dementia (PDD) — the ONLY cholinesterase inhibitor with this on-label indication; modest cognitive benefit and improvement in attention
• Dementia with Lewy bodies — off-label, often the most cholinergic-responsive of the dementias
• Mixed-type vascular dementia — off-label modest benefit

Rivamer is not indicated for: severe Alzheimer's disease (only donepezil is licensed at this stage), mild cognitive impairment, frontotemporal dementia (worsens behavioural symptoms), or as a cognitive enhancer in healthy adults.

Rivamer Dosage and How to Take — SLOW TITRATION

Rivamer comes at 1.5 mg capsules. The 6–8 week titration is mandatory — rivastigmine has the most aggressive GI profile of all AChE inhibitors when given orally.

Standard 6–8 week titration:

• Weeks 1–2: 1.5 mg twice daily (3 mg/day total) with food
• Weeks 3–4: 3 mg twice daily (6 mg/day total)
• Weeks 5–6: 4.5 mg twice daily (9 mg/day total)
• Weeks 7–8 onward: 6 mg twice daily (12 mg/day total) — the maximum maintenance dose

How to Take Rivamer Properly

1. Always take with food. This is the single most important rule for tolerability. Take morning dose with breakfast and evening dose with dinner.
2. Twice daily, 12 hours apart. Rivastigmine has a short half-life — consistency matters.
3. Swallow whole with water. Do not open capsules.
4. If GI side effects are intolerable, drop back to the previous dose for another 2 weeks before re-attempting the up-titration. The transdermal patch (not stocked here, but available worldwide) reduces GI side effects by 60–70% and is the standard rescue for oral intolerance.
5. If treatment is interrupted for more than 3 days, restart at 1.5 mg twice daily and re-titrate. Skipping the re-titration after a break causes severe GI symptoms, sometimes severe enough to need hospital admission for dehydration.
6. Caregiver supervision is critical. Patients with Alzheimer's or Parkinson's dementia rarely manage twice-daily food-timed dosing reliably without support.
7. Re-assess after 6 months with formal cognitive testing (MMSE or MoCA).
8. Consider switching to the transdermal patch if GI side effects persist on the lowest oral dose. The patch achieves the same plasma rivastigmine levels with much lower peak-trough variation.

Side Effects of Rivamer

Common (highest GI burden of all oral AChE inhibitors):

• Severe nausea and vomiting (particularly during titration)
• Diarrhoea
• Anorexia and weight loss
• Dizziness, headache
• Muscle cramps
• Tremor (especially in patients with Parkinson's)
• Insomnia, vivid dreams
• Bradycardia

Less common but important:

• Syncope and falls
• Worsening of Parkinson's motor symptoms (tremor, rigidity)
• Urinary incontinence
• Worsening asthma or COPD
• GI bleeding (especially with NSAIDs)

Rare but seek medical attention:

• Severe bradycardia and complete heart block
• Seizures
• Severe vomiting causing oesophageal rupture
• Pancreatitis
• Severe skin reactions

Warnings and Precautions

• Severe GI side effects: oral rivastigmine has the highest nausea/vomiting burden of any AChE inhibitor. Severe vomiting can cause dehydration, electrolyte disturbance, and oesophageal tears. Stop and re-titrate after a treatment interruption of 3+ days.
• Cardiac: rivastigmine slows heart rate. Caution in sick sinus syndrome, AV block, unexplained syncope. Baseline ECG before starting.
• Parkinson's motor symptoms: rivastigmine can worsen tremor and rigidity in PD patients. Monitor closely; many PD patients tolerate it once dose is established.
• Peptic ulcer disease, NSAID co-prescription: increased GI bleed risk. Co-prescribe a PPI in high-risk patients.
• Asthma and COPD: caution in poorly-controlled disease.
• Anaesthesia: tell the anaesthetist about rivastigmine. It prolongs depolarising muscle relaxants.
• Body weight under 50 kg: caution — greater risk of dose-dependent side effects.
• Urinary obstruction (BPH), seizure history: use cautiously.
• Caregiver support: essential for adherence, food-timing and side-effect monitoring.

Contraindications — Who Should NOT Take Rivamer

• Known hypersensitivity to rivastigmine, other carbamate derivatives, or any capsule excipient
• Severe hepatic impairment (Child-Pugh C)
• Active peptic ulcer disease (until healed)
• Severe symptomatic bradycardia, sick sinus syndrome, second- or third-degree AV block (without pacemaker)
• Severe uncontrolled asthma or COPD
• Recent unexplained syncope
• Severe ongoing vomiting from any cause

Drug Interactions

Storage Instructions

• Store at room temperature, 15–25°C. Protect from light and moisture.
• Keep capsules in the original blister pack until use.
• Do not store in the bathroom — humidity shortens shelf life.
• Keep out of reach of children and patients who may not understand they are medication.
• Return unused capsules to a pharmacy for disposal.

Related Alternatives on MedsBase

Other Alzheimer's and dementia medications stocked on MedsBase:

• Aricep (donepezil 5 / 10 mg)
• Donect (donepezil 10 mg)
• Donemax (donepezil 10 mg)
• Admenta (memantine 5 mg)
• Galamer (galantamine 4 mg)

Helpful reading: Everything you need to know about Alzheimer's disease · Everything to know about dementia · 7 ways to protect your brain health as you age · Best foods for a healthy brain and improved memory.

Frequently Asked Questions

Why is Rivamer the only AChE inhibitor licensed for Parkinson's disease dementia?

Two reasons. First, rivastigmine inhibits both AChE and butyrylcholinesterase (BuChE). BuChE activity is relatively preserved in Parkinson's but reduced in Alzheimer's — so dual inhibition matters more in PDD. Second, rivastigmine had the only large randomised trial (EXPRESS, 2004) showing cognitive benefit specifically in Parkinson's disease dementia. Donepezil and galantamine show similar effects in observational data but lack the formal regulatory indication for PDD.

Why must Rivamer be taken with food?

Food significantly reduces peak rivastigmine concentration and is the single biggest factor in tolerability. Taken on an empty stomach, oral rivastigmine causes severe nausea and vomiting in most patients — sometimes bad enough to need hospital admission. Taken with breakfast and dinner, the same dose is much better tolerated.

When will I or my family member see results from Rivamer?

Visible cognitive benefit at 6–12 weeks after reaching the 9–12 mg/day maintenance dose; peak at 6 months. Like donepezil and galantamine, rivastigmine is symptomatic therapy — it stabilises function for a window of typically 6–18 months. Re-assess with formal cognitive testing at 6 months.

Should I switch to the rivastigmine patch instead?

The transdermal patch (not stocked here but widely available) achieves the same plasma rivastigmine levels with much lower peak-trough variation, reducing GI side effects by 60–70%. The patch is the standard rescue for patients who cannot tolerate oral rivastigmine and is preferred from the start in patients with severe baseline nausea, vomiting from any cause, or carer reports of swallowing difficulty. Discuss with the prescriber if oral side effects are persistent.

Can Rivamer be combined with memantine?

Yes — standard add-on therapy in moderate Alzheimer's disease. Rivastigmine + memantine produces additive cognitive benefit with no significant interaction. Admenta is the standard partner.

Why is the titration so slow?

Rivastigmine has the most aggressive GI side-effect profile of all oral AChE inhibitors. The 6–8 week titration (1.5 mg BD → 3 mg BD → 4.5 mg BD → 6 mg BD) lets the GI tract adapt at each step. Skipping titration causes intolerable nausea, vomiting and diarrhoea, sometimes severe enough to require hospital admission for dehydration.

Will Rivamer make my Parkinson's tremor worse?

Possibly — rivastigmine can mildly worsen tremor and rigidity in some PD patients via increased cholinergic tone. Most patients tolerate it once the dose is established and the cognitive benefit usually outweighs the modest motor side effect. Monitor PD motor symptoms during titration and discuss with the neurologist if tremor worsens significantly.

Can I stop Rivamer if it is not helping?

Discuss with the prescriber. If formal cognitive testing at 6 months shows no benefit, rivastigmine can be tapered and stopped. Like the other AChE inhibitors, abrupt discontinuation can cause cognitive worsening — taper down to the previous dose level for 2 weeks before stopping.

Rivamer vs donepezil — which is right?

If the patient has Parkinson's disease dementia, rivastigmine is first choice (only on-label option). If the patient has Alzheimer's disease and tolerates oral medication well, donepezil is usually first choice on convenience and tolerability grounds (once-daily, cleaner GI profile). Rivastigmine is reasonable for Alzheimer's patients who have not responded to donepezil, particularly if the rivastigmine patch (not stocked here) is available.

Related Alternatives

Other products in Chronic Conditions that customers also view:

• Amaryl
• Dilantin
• Glyxambi (Empagliflozin)
• Amifru
• Cordarone

More options in Alzheimer's Treatment

Ranked by recent MedsBase order volume — what other customers in this category are picking.

Galamer

US$19.00 – US$221.00Fascia di prezzo: da US$19.00 a US$221.00

Aricep

US$26.00 – US$184.00Fascia di prezzo: da US$26.00 a US$184.00

Donect

US$24.00 – US$93.00Fascia di prezzo: da US$24.00 a US$93.00